Kornimate/medical-research-clean huggingface dataset:
effects of graptopetalum paraguayense e. walther on the oxidative stress, antioxidant enzyme activity and inflammation in subjects with metabolic syndrome

Conditions: Metabolic Syndrome

Summary: metabolic syndrome (ms) is a significant risk factor of cardiovascular disease. the purposes of this study are going to investigate the effects of graptopetalum paraguayense e. walther on the oxidative stress, antioxidant enzyme activity and inflammation in subjects with metabolic syndromerelation. the investigators will recruit ms patients(n=50)and the inclusion criteria of ms are according to the bureau of health promotion, department of health in taiwan (2007). the ms subjects are randomly assigned to placebo(n=25) and graptopetalum paraguayense e. walther supplements(n=25)groups. hopefully, the results of this study could provide the information of graptopetalum paraguayense e. walther supplements to what has been know in ms subjects.


Eligibility criteria:
inclusion criteria: * the inclusion criteria of ms in adult are according to the bureau of health promotion, department of health in taiwan (2007), if subjects had 3 of the following 5 characteristics: (1) abdominal obesity (waist circumference \>= 90 cm in men and \>= 80 cm in women), (2) impaired fasting glucose ( \>= 5.6 mmol/l), (3) hypertriglyceridemia ( \>= 1.7 mmol/l), (4) low hdl-c (\ = 130 mmhg and dbp \>= 85 mmhg). subjects using antidiabetic or antihypertensive or lipid-lowering medications were considered to have elevated fasting blood glucose or elevated blood pressures or dyslipidemia, respectively. exclusion criteria: * subjects with liver, renal diseases, undergoing statin therapy, pregnancy women, and taking antioxidant vitamins supplements were excluded.
coronary artery bypass grafting: factors related to late events and saphenous graft patency

Conditions: Myocardial Revascularization; Atherosclerosis

Summary: the purpose of this study is to determine the relations between conventional and unconventional risk factors and adverse clinical events at follow-up (including coronary bypass patency) in patients undergoing surgical myocardial revascularization.

coronary artery bypass grafting represents one of the most frequent surgical procedure performed in the united states and europe. the clinical benefit of myocardial revascularization is related to freedom of adverse cardiovascular events and to graft patency, above all of great saphenous vein, which is nowadays the main autologous vessel used for grafting coronaries different from anterior interventricular artery. unfortunately, phenomena leading to early and, above all, late complications and to graft occlusion are not fully clarified and it so not possible to explain interindividual and temporary variability of progressive stenosis rate only on the basis of classical atherosclerosis risk factors. the aim of our study is to prospectively study the role of conventional risk factors (preoperative risk factors and clinical features) and of unconventional risk factors (genetic polymorphisms, inflammation and coagulation markers) with saphenous late patency and postoperative patients outcome, in particular with regard to adverse clinical events (myocardial infarction, successive stenting procedures, arrhythmias etc.)and to bypass patency. plasma venous samples will be collected the day before surgery, at discharge from the hospital, and at follow-up from patients undergoing on-pump and off-pump coronary artery bypass grafting and stored at -80°c; patients will be followed-up periodically with visits and telephone interviews, and will be also invited to undergo multislice (64 rows) ct scan in order to assess graft patency between 12 and 24 months after surgery. finally the relation between conventional and unconventional risk factors with adverse events at follow-up will be assessed with multivariable statistical models.

Eligibility criteria:
inclusion criteria: * men and women age 18 to 89 * elective primary cabg * female patients must be non-lactating and not pregnant * able and willing to comply with study requirements by signing a consent form exclusion criteria * concomitant surgery * major end organ dysfunction * serious intercurrent illness or infection * known coagulation disorders * emergencies

Keywords: coronary artery bypass grafting (cabg) outcome saphenous graft patency biochemical factors genomics
heparin-induced thrombocytopenia (hit ii) in liver transplant recipients

Conditions: Heparin-induced Thrombocytopenia; Liver Transplantation

Summary: in a prospective observational study the incidence of heparin-induced thrombocytopenia (hit) type 2 after orthotopic liver transplantation, associated factors, and hemostaseological findings in thrombocytes and anti-body patterns is going to be investigated.

the investigators examined the frequency of anti-pf4/heparin antibodies (igg/m/a; eia) and their functional activity (hipa) in 38 whole organ deceased donor liver transplant recipients. additionally, demographic, clinical, donor- and recipient-specific parameters and laboratory findings (alat, asat, cholinesterase) were investigated.

Eligibility criteria:
inclusion criteria: * all consecutive liver transplant recipients between 01/2010 and 08/2011 who * were transplanted at our center after allocation of a liver graft via eurotransplant exclusion criteria: * patient's refusal to participate in prospective observation

Keywords: liver transplantation thrombocytes heparin-induced thrombocytopenia multivariate analysis of associated factors of hit 2 after olt laboratory investigations of hit-antibodies
isoflavones and radiation therapy in treating patients with localized prostate cancer

Conditions: Prostate Cancer

Summary: rationale: eating a diet high in soy foods may slow the progression of some types of cancer. isoflavones are compounds found in soy food that may slow the growth of prostate cancer cells and prevent further development of prostate cancer. radiation therapy uses high-energy x-rays to kill tumor cells. giving isoflavones together with radiation therapy may be an effective treatment for prostate cancer. purpose: this randomized phase ii trial is studying the side effects and how well giving isoflavones together with radiation therapy works in treating patients with localized prostate cancer.

objectives: * determine the effect of soy protein isolate (isoflavones) and radiotherapy on the modulation of biomarkers in patients with localized prostate cancer. * determine the toxicity of this regimen in these patients. * determine the effect of this regimen on the quality of life of these patients. outline: this is a randomized, placebo-controlled study. patients are randomized to 1 of 2 treatment arms. * arm i: patients receive oral soy protein isolate (isoflavones) twice daily for 6 months in the absence of disease progression or unacceptable toxicity. * arm ii: patients receive an oral placebo twice daily for 6 months in the absence of disease progression or unacceptable toxicity. in both arms, patients also undergo radiotherapy while receiving isoflavones or placebo. quality of life is assessed periodically. projected accrual: a total of 70 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed adenocarcinoma of the prostate that is localized to the prostate gland * must be scheduled to receive curative radiotherapy for prostate cancer * not eligible for a higher priority study at the karmanos cancer institute patient characteristics: performance status * 0-3 life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified other * no organ function restrictions prior concurrent therapy: chemotherapy * no prior chemotherapy endocrine therapy * no prior hormonal therapy radiotherapy * see disease characteristics other * no other concurrent micronutrient supplements, herbs, or vitamins except 1 daily multivitamin

Keywords: stage i prostate cancer stage ii prostate cancer
electroencephalographic monitoring in patients treated by deep brain stimulation

Conditions: Motor Disorders; Psychiatric Disorder

Summary: this protocol aims to develop the use of behavioral and electroencephalographic measures during cognitive tasks in patients treated with deep brain stimulation during the stimulation parameters adjustments. the main clinical goal of this protocol is to find behavioral and or electroencephalographic markers to evaluates the right targeting of stimulation electrodes. on the more fundamental point of view, the study of those data can be used to understand better the action mechanisms of deep brain stimulation.

this protocol aims to understand how brain regions are modulated by deep brain stimulation using scalp electroencephalographic recordings. this protocol covers many pathologies which are thought to relate to different brain networks impairements and are therefore complementary in the understanding of cortical activation and modulation of this activation by deep brain stimulation. these diseases are motor (parkinson..) and psychiatric (obsessive compulsive disorders, treatment resistant depression..). to activate brain networks of interest, either implicating brain regions dysfunctional in the diseases or brain regions stimulated by the electrode, the investigators can use cognitive task which are know to involve those networks, for instance motor task for motor diseases as clicking with a computer mouse when presented with a specific type of stimulus on the screen. eeg recordings can then be processed to retrieve cortical activation and modulation of this activation with stimulation (using an on dbs off dbs procedure) during task processing. these data are also very precious to study brain dynamic networks and their modulation by dbs. after analysis of these results, this protocol aims to be used in order to refine targeting, for instance when correlating cortical modulation with dbs and clinical improvement with electrode positions.

Eligibility criteria:
inclusion criteria: * patient treated with dbs * study inclusion written agreement by the patient or his legal representant * intellectual capacities compatible with cognitive task and eeg recordings * french native speaker and capacity to understand the study processes and particularly to fill in the auto questionaires * patients abled to give an enlighted agreement * patients who have an health insurance coverage exclusion criteria: * people who fill in the articles l1121-5 to l1121-8 or the public health code * patients who don't stand the transient interruption of stimulation * severe concomitant disease * disease which impose a treatment which modulates vigilance * cognitive alteration (mattis\<130)

Keywords: deep brain stimulation eeg
effects of a limited almond consumption after a weight loss plan on weight maintenance

Conditions: Obesity; Overweight

Summary: the purpose of this study is to assess the effects of limited portion of almond consumption after a successful weight loss by a comprehensive weight loss plan (novindiet plan) on weight maintenance in obese female adults.


Eligibility criteria:
inclusion criteria: * female * 18-45 years of age. * body mass index (bmi) between 23-30 kg/ m² who lost at least 10% of her initial weight by the diet plan. * must be able to have moderate exercise. * must be interested to keep weight loss. exclusion criteria: * no allergy to nut products * pregnancy or lactation during the previous 6 months, or planned pregnancy in the next 6 months. * taking medications that could affect metabolism or change body weight. * report heart problems, chest pain, and cancer within the last five years. * smoking * menopause * diagnosis of any chronic disease such as fatty liver, cancer, chemo/radio therapy, heart disease, immune compromised conditions, abnormal thyroid hormone level.

Keywords: almond weight loss weight maintenance hypoenergetic diet
feasibility of collateral information review and its impact on clinical decision-making

Conditions: Depressive Disorder; Anxiety Disorders

Summary: this project will investigate how review of collateral information sources (cis) may impact clinical decision-making across the lifespan.

this study aims to explore how reviewing collateral information sources (cis) may affect clinical decision-making for clinicians treating participants with varied mood disorders. investigators will assess the types of collateral information used in the clinical setting and treatment decisions made after a clinical session. we will gather this information from interested clinicians who will provide this information after each patient visit over the course of one week.

Eligibility criteria:
inclusion criteria: 1. credentialed to provide psychopharmacology or psychotherapy at mclean and licensed by the state of massachusetts 2. practice pharmacotherapy and either adjunctive or stand-alone evidence-based psychotherapy (e.g., cbt, dbt, supportive psychotherapy, etc.) 3. fluent in english exclusion criteria: * clinicians who do not meet the inclusion criteria detailed above
comparison of classification standards of bpd in premature infants

Conditions: Bronchopulmonary Dysplasia

Summary: bronchopulmonary dysplasia of premature infants is a common respiratory disease in premature infants. long-term complications such as recurrent respiratory infection and abnormal lung function may occur in the survivors, and may increase the risk of dysplasia of the nervous system. in the past 30 years, although the monitoring and treatment technology of premature infants has been significantly improved, the incidence of bpd still shows no downward trend, and effective treatment and prevention methods for bpd are still lacking. the progress of clinical research on bpd is slow, one of the important reasons is that the definition of bpd is still not consistent, and its diagnostic and grading standards lack objectivity. to summarize the development of diagnostic criteria for bpd in the past 30 years, there are still the following disadvantages. 1. 2. in the above study, all proposed alternative bpd classification standards did not completely separate hfnc and niv. in view of this, this study separated hfnc and other niv to form a new revised bpd classification standard. on this basis, a nested case-control study was conducted to compare the differences between the newly proposed classification standards and nichd standards in 2001, rosemary standards in 2018 and jensen standards in predicting long-term respiratory outcomes and other systemic complications in premature infants, so as to provide a standard for more accurate diagnosis and evaluation of bpd in premature infants.


Eligibility criteria:
inclusion criteria: * premature infants whose gestational age is less than 32 weeks; * hospital stay ≥14 days; * complete clinical medical records, including effective follow-up information exclusion criteria: * congenital heart and lung malformation and specific chromosomal diseases; * children abandon treatment halfway; * death of children due to factors other than respiratory system.

Keywords: bronchopulmonary dysplasia high-flow nasal cannula noninvasive ventilation ventilation mode premature infant
sacroiliac joint dysfunction and spinal mobility in women with primary dysmenorrhoea

Conditions: Primary Dysmenorrhea

Summary: evaluation of sacroiliac joint dysfunction in young women with primary dysmenorrhoea using joint provocation and mobility tests and spinal mobility using spinal mouse and investigation of the relationship between primary dysmenorrhoea, sacroiliac joint dysfunction and spinal mobility.

dysmenorrhoea is defined as pathological symptoms associated with menstruation, manifested by abdominal cramps and pain during menstruation and interfering with social life. the pain is of uterine origin and is one of the most common gynaecological disorders in women of childbearing age. it is divided into two types as primary dysmenorrhoea and secondary dysmenorrhoea. primary dysmenorrhoea is the most common form and is characterised by cramping pelvic pain that begins shortly before or at the onset of menstruation and lasts for one to three days. it usually begins during puberty and manifests itself with painful menstruation in women with normal pelvic anatomy. sacroiliac joint dysfunction is thought to be caused by different causes such as sacroiliac strain, sacroiliac instability and sacroiliac arthritis. one of the distinguishing features is local tenderness in the sacroiliac joint. there are limited number of studies showing the relationship between sacroiliac joint dysfunction and menstrual cycle. studies have shown that osteopathic manual therapy techniques applied to the pelvis are effective in alleviating the severity of primary dysmenorrhoea. at the same time, researchers have reported that mobilisation applied to the lumbopelvic regions is good for menstrual pain. thus, it can be said that mobility is important in primary dysmenorrhoea.

Eligibility criteria:
inclusion criteria: * being a woman between the ages of 18-24 * being single * have a regular menstrual cycle (every 24-32 days) * duration of menstruation between 3-7 days * severity of primary dysmenorrhoea according to vas exclusion criteria: * refusal to participate * diagnosis as a patient with secondary dysmenorrhoea * presence of chronic disease * regular medication * polycystic ovary syndrome * pelvic inflammatory diseases * history of uterine, cervical or ovarian cancer * previous gynaecological interventions

Keywords: pain sacroiliac joint dysfunction spinal mobility
map-calcification: micrornas as potential biomarkers for coronary artery calcification

Conditions: Coronary Artery Calcification; Coronary Artery Disease; Osteoporosis; Osteopenia

Summary: coronary artery disease (cad) remains the leading cause of mortality in the uk with an estimated 80,000 fatalities in 2010. coronary artery calcification (cac) is associated with atherosclerotic plaque burden and cardiovascular mortality. mechanisms underlying isolated cac have not been as yet been fully explained. micrornas (mirnas), known to act as regulators of gene expression, have also emerged as powerful biomarkers in the diagnosis and prognosis of cardiovascular disorders and may be used in the detection of cac. we aim to investigate the potential for a "microrna-signature" in patients with cac by performing a prospective, case-controlled study to identify pathways associated with cac in humans. previous research has demonstrated an inverse relationship between cac and bone mineral density (bmd), suggesting that these processes may be linked. in a further substudy we plan to define the relationship between cac and bmd as well as a number of markers of bone metabolism.

patients will be prospectively enrolled whilst attending for elective coronary ct (computed tomography) angiography including a coronary calcium score, at the royal surrey county hospital. data regarding demographic and clinical characteristics of patients will be collected. peripheral venous blood sampling will take place on this occasion. coronary artery calcification scores will be estimated by a radiologist using default software. patients eligible for the bone metabolism substudy will be required to attend the university of surrey for peripheral quantitative computed tomography (pqct) of bone mineral composition of the radius. in the intervening period we will ask them to complete a 4-day food diary and wear a uv dosimeter, the latter to assess typical uv exposure, for one week.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patient is able to provide written, informed consent exclusion criteria: * age \> 65 years * diabetes mellitus * glomerular filtration rate ≤ 60 ml/min * abnormal serum calcium * history or clinical features of cardiac failure * systemic inflammatory disease * peripheral vascular disease * previous history of percutaneous coronary intervention (pci) * previous history of coronary artery bypass grafting (cabg) * previous history of reno-vascular disease * active infection * active malignancy additional clinical exclusion criteria for our sub-study are: * regular use of sunbeds * a sun holiday one month prior to or plans for sun holiday within the study * use of vitamin d supplements * consumption of alcohol above recommended levels * pregnancy or planned pregnancy * use of a veil
umbilical cord derived mesenchymal stem cells therapy in ischemic cardiomyopathy

Conditions: Ischemic Cardiomyopathy

Summary: the aim of the present study is to investigate safety and efficacy of intramyocardial implantation of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy .

coronary artery disease (cad) is a common disorder that can lead to heart failure. not all people with cad are eligible for today's standard treatments. one new treatment approach uses umbilical cord blood derived mesenchymal stem cells-specialized cells capable of developing into other types of cells-to stimulate growth of new blood vessels for the heart. the aim of the present study is to investigate safety and efficacy of intramyocardial implantation of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy .

Eligibility criteria:
inclusion criteria: 1. age from 30 to 80 years 2. ischemic cardiomyopathy 3. left ventricular infarction area seriously low movement to no movement 4. the low whole left ventricular systolic function (lvef 45% or less) 5. have line or quasi coronary interventional treatment 6. willing to accept patients with follow-up evaluation 7. have signed informed consent form approved by the ethics committee exclusion criteria: 1. non elevation between s-wave and t-wave in patients with acute myocardial infarction 2. no function damage in patients with acute myocardial infarction 3. acute myocardial infarction complicated with left ventricular aneurysm intends to do surgery 4. complications of acute myocardial infarction with other machines (including: ventricular septal perforation, papillary muscle rupture, etc.) 5. acute infectious diseases 6. blood system diseases, such as thrombocytopenia, severe anemia, leukemia, etc 7. severe renal disease, creatinine clearance \ 265 umol/l 8. laboratory tests suggest abnormal liver function, glutamate-pyruvate transaminase (alt) \> 4 times the upper limit of normal 9. unstable cerebral lesions 10. malignant tumor 11. cognitive dysfunction and dementia patients, patients with severe mental illness 12. patients with severe physical disabilities can't regular follow-up 13. other serious uncontrolled system disease 14. to prepare or have the pregnancy women patients 15. have a percutaneous coronary intervention contraindications: high-risk patients, such as the digestive tract, and intracranial hemorrhage or contrast allergy 16. cannot use the test dose atorvastatin 17. is not completed in accordance with the requirements for test the timing of the magnetic resonance imaging (mri), pet, spect, follow-up testing (e.g., patients with implanted pacemakers or artificial joint) 18. patients unable or unwilling to sign a consent form